• Publications
  • Influence
The natural history of multiple system atrophy: a prospective European cohort study
TLDR
The final analysis of a prospective multicentre study by the European MSA Study Group provides new insights into the evolution of MSA based on a follow-up period that exceeds that of previous studies. Expand
Red flags for multiple system atrophy
TLDR
A combination of two out of six red flag categories as additional diagnostic criteria for probable MSA‐P is proposed and 76.5% of them would have been correctly diagnosed as probable Msa‐P 15.9 months earlier than with the Consensus criteria alone. Expand
Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry
TLDR
This largest clinical series of MSA patients reported so far shows that the disease presents uniformly across Europe, and the observed differences in diagnostic and therapeutic management including lack of therapy for dysautonomia emphasize the need for future guidelines in these areas. Expand
Health‐related quality of life in multiple system atrophy
TLDR
This report is the first study to show that Hr‐QoL is significantly impaired in MSA, and therapeutic management, therefore, should concentrate upon these aspects of the disease. Expand
Diffusion weighted imaging best discriminates PD from MSA‐P: A comparison with tilt table testing and heart MIBG scintigraphy
TLDR
The data suggest that DWI is superior to both tilt table testing and MIBG scintigraphy in the differential diagnosis of PD versus MSA‐P, and regional trace of the diffusion tensor values were determined in the putamina. Expand
Orthostatic hypotension and attention in Parkinson’s disease with and without dementia
TLDR
It is concluded that OH is frequent in PDD and should be addressed therapeutically since it may exacerbate attentional dysfunction, and blood pressure and heart rate changes during tilt were determined. Expand
Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)
TLDR
This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function, and preliminary PET‐data suggest that minocyCline may interfere with microglial activation. Expand
The European Multiple System Atrophy-Study Group (EMSA-SG)
TLDR
Data about the natural history and prognosis of MSA as well as surrogate markers of disease process allow planning and implementation of multi-centre phase II/III neuroprotective intervention trials within the next years more effectively. Expand
Progression of dysautonomia in multiple system atrophy: a prospective study of self‐perceived impairment
TLDR
The data suggest that dysautonomia should be recognized as a key target for therapeutic intervention in MSA and its evolution over time is suggested. Expand
Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
TLDR
The neuroprotective potential of erythropoietin is investigated in (proteolipid protein)‐α‐ synuclein transgenic mice exposed to 3‐nitropropionic acid featuring multiple system atrophy‐like pathology including oligodendroglial α‐synuclein inclusions and selective neuronal degeneration. Expand
...
1
2
...